Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep 20;4(3):384-386.
doi: 10.1016/j.jaccao.2022.07.001. eCollection 2022 Sep.

ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity

Jenica N Upshaw  1 , Richard Travers  2   3 , Iris Z Jaffe  1   3
Affiliations
Editorial

ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity

Jenica N Upshaw et al. JACC CardioOncol. .
No abstract available

Keywords: BCR-ABL kinase inhibitors; chronic myeloid leukemia; endothelial cell; vascular toxicity.

PubMed Disclaimer

Conflict of interest statement

This work was supported by grants from the National Institutes of Health HL155078 (to Dr Jaffe), NIH K08HL146959 (to Dr Upshaw), and CA243542 (to Drs Jaffe and Upshaw). Dr Travers has reported that he has no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
See this image and copyright information in PMC

Comment on

References

    1. Zhong L., Li Y., Xiong L., et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201. - PMC - PubMed
    1. Douxfils J., Haguet H., Mullier F., Chatelain C., Graux C., Dogne J.M. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2(5):625–632. - PubMed
    1. Yu B., Osman A.E.G., Sladojevic N., et al. Involvement of Rho-associated coiled-coil containing kinase (ROCK) in BCR-ABL1 tyrosine kinase inhibitor cardiovascular toxicity. J Am Coll Cardiol CardioOnc. 2022;4:371–383. - PMC - PubMed
    1. Haguet H., Douxfils J., Chatelain C., Graux C., Mullier F., Dogne J.M. BCR-ABL tyrosine kinase inhibitors: which mechanism(s) may explain the risk of thrombosis? TH Open. 2018;02(01):e68–e88. - PMC - PubMed
    1. Dasgupta S.K., Le A., Vijayan K.V., Thiagarajan P. Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA-ROCK pathway. Cancer Med. 2017;6(4):809–818. - PMC - PubMed

Publication types

LinkOut - more resources